GlassScriptPhysician profile
Stephen Todd Greenberg
NPI 1619032240
$32,140.83
in general payments reported to CMS, 2019-2025
34 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,108 · 2020: $1,726 · 2021: $17K · 2022: $6,203 · 2023: $950 · 2024: $662 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19,754.71 | 2019-2022 | |
| Sientra, INC. | $5,213.64 | 2019-2022 | |
| Mentor Worldwide LLC | $1,962.73 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Merz North America, INC. | $1,708.31 | 2019-2023 | |
| Galderma Laboratories, L.P. | $1,044.53 | 2019-2025 | Dysport |
| Musculoskeletal Transplant Foundation INC. | $229.76 | 2019-2024 | |
| Leo Pharma INC. | $226.55 | 2020-2021 | |
| Motiva USA, LLC | $222.94 | 2025 | |
| Sun Pharmaceutical Industries INC. | $208.56 | 2020-2025 | Absorica Ld, Winlevi |
| Polynovo North America LLC | $184.32 | 2024 | Novosorb Btm |
| Abbvie INC. | $172.71 | 2025 | |
| Revance Therapeutics, INC. | $169.02 | 2024-2025 | Daxxify |
| Teva Pharmaceuticals USA, INC. | $138.02 | 2019 | |
| Medline Industries LP | $103.59 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.38 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $80.89 | 2020-2022 | |
| Incyte Corporation | $75.11 | 2022-2023 | Opzelura |
| Apyx Medical Corporation | $74.48 | 2019-2020 | |
| Kerecis Limited | $55.88 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Almirall LLC | $55.16 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $48.28 | 2022-2023 | Seglentis |
| Janssen Biotech, INC. | $47.25 | 2020-2022 | |
| Coopersurgical, INC. | $36.97 | 2023 | Fisherbrand Disposable Liquid Infant Heel Warmer |
| Acelrx Pharmaceuticals, INC. | $36.88 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $32.17 | 2022-2023 | Bridion |
| Solta Medical, A Division of Bausch Health US, LLC | $24.45 | 2025 | |
| Stryker Corporation | $24.16 | 2023 | |
| Verrica Pharmaceuticals INC. | $21.66 | 2023 | Ycanth |
| Mission Pharmacal Company | $19.21 | 2022 | |
| Vertical Pharmaceuticals, LLC | $18.91 | 2024 | Dsuvia |
| Trevena, INC. | $15.87 | 2021 | |
| Dermira, INC. | $15.80 | 2021 | |
| Sebela Pharmaceuticals INC. | $14.98 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.